Processa Pharmaceuticals Business Summary

Processa Pharmaceuticals, Inc. (PCSA) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, milestone payments, and collaborative partnerships rather than direct product sales. The company’s business model is centered on its proprietary "Regulatory Science Approach," which involves re-engineering existing FDA-approved chemotherapies to improve their safety and efficacy profiles. Its primary business segments are divided into Next Generation Chemotherapy (NGC) oncology programs—led by its Phase 2 candidate NGC-Cap (PCS6422) for metastatic breast cancer—and a portfolio of non-core assets, such as PCS12852 for gastroparesis, which are monetized through out-licensing deals. Direct competitors include GlycoMimetics, Galecto, Inovio Pharmaceuticals, and ACADIA Pharmaceuticals; Processa distinguishes itself by focusing on modifying the metabolism and distribution of established drugs to enhance the therapeutic index rather than discovering entirely new chemical entities. The leadership team is anchored by a founding group with extensive pedigrees in drug development and regulatory affairs, including Co-Founders Dr. David Young (President of R&D), Dr. Sian Bigora (Chief Development Officer), Patrick Lin (Chief Business & Strategy Officer), and Wendy Guy (Chief Administrative Officer). CEO George Ng, appointed in 2023, brings executive experience from Calidi Biotherapeutics and Scilex Pharmaceuticals, while CFO Russell Skibsted, who joined in 2024, offers three decades of financial expertise from roles at Alimera Sciences and GE Capital. The company is overseen by a board chaired by Justin Yorke and maintains significant strategic backing, notably from the Chiliz Group, which increased its stake to 13% in February 2026, and Yuhan Corporation.